Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue

MT Newswires Live06-23

Imunon (IMNN) said Tuesday an independent data monitoring committee recommended continuing the phase 3 trial evaluating its experimental therapy, IMNN-001, in combination with standard chemotherapy for women with advanced ovarian cancer, with no changes to the study.

The company said the trial's primary endpoint is overall survival and includes two planned interim analyses that could support an accelerated marketing application if statistical significance is achieved early.

The trial has enrolled 27 patients so far and Imunon said it expects to complete enrollment of about 80 patients by the end Q1 2027.

Imunon shares were more than 7% higher in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645983939?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645983939","market":"us","top_or_hot":-1,"title":"Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue","media":"MT Newswires Live","content":"<html><body><p> Imunon (IMNN) said Tuesday an independent data monitoring committee recommended continuing the phase 3 trial evaluating its experimental therapy, IMNN-001, in combination with standard chemotherapy for women with advanced ovarian cancer, with no changes to the study.</p><p>The company said the trial's primary endpoint is overall survival and includes two planned interim analyses that could support an accelerated marketing application if statistical significance is achieved early.</p><p>The trial has enrolled 27 patients so far and Imunon said it expects to complete enrollment of about 80 patients by the end Q1 2027.</p><p>Imunon shares were more than 7% higher in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImunon's Phase 3 Ovarian Cancer Trial Cleared to Continue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-23 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imunon (IMNN) said Tuesday an independent data monitoring committee recommended continuing the phase 3 trial evaluating its experimental therapy, IMNN-001, in combination with standard chemotherapy for women with advanced ovarian cancer, with no changes to the study.</p><p>The company said the trial's primary endpoint is overall survival and includes two planned interim analyses that could support an accelerated marketing application if statistical significance is achieved early.</p><p>The trial has enrolled 27 patients so far and Imunon said it expects to complete enrollment of about 80 patients by the end Q1 2027.</p><p>Imunon shares were more than 7% higher in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645983939","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645983939","pubTimestamp":1782218890,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imunon  said Tuesday an independent data monitoring committee recommended continuing the phase 3 trial evaluating its experimental therapy, IMNN-001, in combination with standard chemotherapy for women with advanced ovarian cancer, with no changes to the study.The company said the trial's primary endpoint is overall survival and includes two planned interim analyses that could support an accelerated marketing application if statistical significance is achieved early.The trial has enrolled 27 patients so far and Imunon said it expects to complete enrollment of about 80 patients by the end Q1 2027.Imunon shares were more than 7% higher in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMNN":"Imunon, Inc."},"translate_title":"Imunon卵巢癌3期试验获准继续进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNN":1},"content_text":"Imunon (IMNN) said Tuesday an independent data monitoring committee recommended continuing the phase 3 trial evaluating its experimental therapy, IMNN-001, in combination with standard chemotherapy for women with advanced ovarian cancer, with no changes to the study.The company said the trial's primary endpoint is overall survival and includes two planned interim analyses that could support an accelerated marketing application if statistical significance is achieved early.The trial has enrolled 27 patients so far and Imunon said it expects to complete enrollment of about 80 patients by the end Q1 2027.Imunon shares were more than 7% higher in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645983939","isCrawlerRequest":true}